Dr. John Giannios acquired his FRSM (London), MRSC (Cambridge) and M/D (London) in Translational Cancer Medicine. He has studied Medicine with four postgraduate degrees in Translational Medicine which were earned with Distinction from the Medical School of the University of Edinburgh and London. He is the project leader of Translational Cancer Medicine in Medical University Hospitals discovering as a cancer researcher novel genomic/epigenomic personalised medicine therapeutic approaches, molecular diagnostics based on pharmacogenomics and molecular oncology research involving nanomedicine, nanosurgery and oncogenomics/epigenomics. He is discovering with Next Generation Sequencing and RNA-seq in American Medical Universities, novel cancer related genes as targets for novel diagnostics and biological treatments under a personalized cancer medicine approach based on pharmacogenomics, pharmacoepigenomics and oncotheranostics. Furthermore, he is a genomic counselor for preventive oncology involving hereditary cancers, screening, diagnosis and oncotheranostics for personalized anticancer treatment based on the tumourís genomic and epigenomic profile. He is the president and chief-editor of the Hellenic and International Society of Molecular and Genomic Medicine and Research organizing three national oncology congresses up to now with international participation. Furthermore, he is the president of the International Association of the Personalised Perioperative Medicine and Laser, Robotic and GENOMIC NANOSURGERY. Specifically, he has invented many new anticancer treatments based on molecular oncology and nanosurgery after adjuvant treatment facilitated by nanomedicine focusing on nano-oncology and femto second laser leading to the eradication of cancer stem cells with nanophotothermolysis. Also he has invented many stem cell therapies for regenerative medicine which he has presented in American Congresses and in Canada. He has been organised as President of the scientific and organising committee of many molecular oncology congresses.
Evidence based dentistry; Molecular dentistry; Genomic and Epigenomic Aspects of Oral Health; Nanotechnology in dental science; Prevention, diagnosis and treatment of oral diseases on an individualized basis; Pharmacogenomics in personalized oral medicine; Chemoprevention of oral tumours.